Pharma Focus Asia

Radiopharm Theranostics Partners with GenesisCare

Tuesday, March 28, 2023

Radiopharm Theranostics and GenesisCare have announced a new two-year strategic research collaboration to develop novel radiopharmaceuticals for some complex, hard-to-treat cancers. Through the partnership, Radiopharm Theranostics and GenesisCare will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals, focusing on areas of high unmet need in oncology.

As part of the collaboration, GenesisCare’s Contract Research Organisation (CRO) and Imaging Research Organisation (IRO), will implement three Phase 1 clinical trials in Australia, involving Radiopharm’s platform of radiopharmaceutical nanobodies.

The three Phase 1 clinical trials to be conducted by GenesisCare for Radiopharm under the research partnership are:
1. Phase 1 trial involving Radiopharm’s proprietary nanobody from its Nano-mAbs platform which targets the PDL1 expression in non-small cell lung cancer
2. Phase 1 trial involving Radiopharm’s PTPu targeting peptide in Brain Tumours
3. Phase 1 trial involving Radiopharm’s PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells.

This R&D collaboration brings together two Australian healthcare companies interested in researching and developing new treatments in Australia.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024